Semaglutide's patent expiry in India opens a multi-billion dollar market for generic drug makers, with over 40 firms planning launches. However, a quality lapse at Dr. Reddy's threatens India's reputation as a reliable supplier of 20% of the world's generic medicines, exposing systemic chinks in manufacturing compliance.
Exam Lens
Quick Exam Facts From News
1-Minute Revision
- ›India's share of global generics: 20% by volume
- ›Indian firms planning semaglutide launch: Over 40
- ›Target this Data: India supplies 20% of the world's generic medicines by volume; API market size ₹1,31,700 crore (2025); PLI outlay ₹15,000 crore.
- ›Target this Nodal Body: The Ministry of Chemicals and Fertilizers (Department of Pharmaceuticals) administers the PLI scheme for pharma (inferred, not explicitly mentioned but standard).
- ›Target this Legal Point: Patent expiry of semaglutide in India occurred in March 2026; the Supreme Court's 2013 verdict on imatinib patent (Novartis) is a landmark case.
Mastered this topic? Test your knowledge with a full MCQ quiz.
Practice exam-style questions, track your score, and strengthen your recall.